ARTICLE | Clinical News
Flutiform fluticasone propionate/formoterol: Phase III data
September 5, 2016 7:00 AM UTC
Top-line data from the double-blind, international Phase III EFFECT trial in 1,767 COPD patients ages >=40 showed that twice-daily 250/10 ug inhaled flutiform for 52 weeks missed the primary endpoint ...